Peanut allergen-immune receptor complex

Peanut allergens, primarily Ara h 1, Ara h 2, and Ara h 6, trigger severe allergic reactions by interacting with various endogenous immune receptors (nih.gov, 2011; nih.gov, 2022). The most critical interaction involves the cross-linking of allergen-specific IgE bound to the high-affinity IgE receptor (FcεRI) on mast cells and basophils, leading to the release of inflammatory mediators like histamine and leukotrienes (frontiersin.org, 2017; news-medical.net, 2022). Additionally, peanut allergens interact with innate immune receptors such as DC-SIGN (CD209) and Toll-like receptors (TLR2, TLR4) on dendritic cells, which promotes Th2 cell differentiation and IgE production (usda.gov, 2013; nih.gov, 2015). Therapeutic strategies targeting this axis include IgE-neutralizing antibodies like Omalizumab, which prevent IgE from binding to FcεRI, and oral immunotherapy (e.g., Palforzia) to induce desensitization (nih.gov, 2022; d-nb.info, 2019). Experimental monoclonal antibodies are also being developed to neutralize specific major allergens like Ara h 2 to prevent receptor cross-linking (nih.gov, 2023). Monitoring patient response typically involves measuring allergen-specific IgE levels and performing basophil activation tests, while safety concerns focus on the risk of anaphylaxis and eosinophilic esophagitis (thermofisher.com, 2023; medchemexpress.com, 2022).

Other names

Peanut allergen-receptor interactionPeanut allergen-IgE-FcεRI axisPeanut allergen-innate receptor interactionPeanut allergens via endogenous immune receptors

The primary mechanism of action for drugs targeting this complex involves neutralizing the allergens or IgE to prevent the cross-linking of the high-affinity IgE receptor (FcεRI) on effector cells. Immunotherapy (e.g., Palforzia) works by inducing immunological desensitization and shifting the immune response toward tolerance, while biologicals like Omalizumab sequester free IgE. Other approaches include blocking Th2-skewing cytokines (IL-4, IL-13, TSLP) or utilizing monoclonal antibodies to specifically neutralize major allergens like Ara h 2.